OBJECTIVE: To explore the efficacy of Kangfuxin liquid combined with anti-tuberculosis drugs in the treatment of intestinal tuberculosis and effects on levels of vascular endothelial growth factor（VEGF） and nuclear factor-κB（NF-κB） in serum and intestinal mucosa. METHODS: Totally 60 patients with intestinal tuberculosis admitted into Hebei Chest Hospital from Sept. 2019 to Jan. 2021 were extracted to be divided into the routine group and combined group via the random number table

with 30 cases in each group. The routine group was treated with anti-tuberculosis drugs

while the combined group were additionally given Kangfuxin liquid based on the routine group. The efficacy

symptom improvement time

serum and intestinal mucosa related indicators before and after treatment

liver function injury and adverse drug reactions in two groups were observed. RESULTS: The total effective rate of the combined group was 93.33%（28/30）

significantly higher than that of the routine group 73.33%（22/30）

the difference was statistically significant（P<0.05）. Symptom improvement time in the combined group was significantly shorter than that in the routine group

the difference was statistically significant（P<0.05）. After treatment

the VEGF

NF-κB

tumor necrosis factor alpha（TNF-α）

interleukin-1β（IL-1β） and C-reactive protein（CRP） in serum

and VEGF

NF-κB and protein kinase（PAK） in intestinal mucosa in two groups were significantly improved. After treatment

the levels of VEGF in serum in the combined group were significantly higher than those in the routine group

the levels of NF-κB

TNF-α

IL-1β and CRP in serum in the combined group were significantly lower than those in the routine group; the levels of VEGF in intestinal mucosa in the combined group were significantly higher than those in the routine group

the levels of NF-κB and PAK in intestinal mucosa were significantly lower than those in the routine group

with statistically significant difference（P<0.05）. There were no significant differences in the incidence of liver function injury[23.33%（7/30） and 30.00%（9/30）] and the incidence of adverse drug reactions[16.67%（5/30） and 23.33%（7/30）] between the combined group and the routine group（P>0.05）. CONCLUSIONS: The therapeutic efficacy of Kangfuxin liquid in the treatment of intestinal tuberculosis is significant. The mechanism may be that Kangfuxin liquid inhibits the inflammatory response and promotes mucosal repair by inhibiting NF-κB expression and up-regulating VEGF levels

which in turn improves patients’ related symptoms and enhances the therapeutic effects.